Atypical development of opportunistic infection or malignancy on the background of ART, manifested as: localized disease and/or excessive or atypical inflammatory response in affected tissues and/or progression of organ or systemic dysfunction with reactivation of previously existing, but treated/controlled diseases due to the course of therapy preceding ART
Decrease in HIV RNA level in blood by more than 10-fold from baseline
Increase in CD4 lymphocyte count in blood after initiation of ART
Strengthening of specific immune response
Spontaneous resolution of secondary diseases during continuation of ART